Daptomycin belongs to the antibiotic class and achieves its selective antibacterial effect by inhibiting a bacterial enzyme or structural component essential for pathogen survival and replication while maintaining a defined safety margin against mammalian cell toxicity. The selectivity index between the antibacterially effective concentration and the mammalian cytotoxic concentration defines the therapeutic window. PDE derivation for Daptomycin draws on the critical repeat-dose toxicity study in rodents or higher species, with the NOAEL serving as the point of departure before application of composite uncertainty factors.
The intraspecies uncertainty factor F2 for Daptomycin covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with organ impairment affe
